|
|
|

|
| AIDS Updates |
|
|
DRUG
INTERACTIONS IN HIV THERAPY
A Clinician's Guide |
|
|
THE MEDICATION
QUESTIONNAIRE
|
Before prescribing a new drug, the HIV physician needs
to ascertain the following:
|
1 What is the patient taking?
|
It is important to take a complete
medication history from the patient, and record it at
every clinic visit.
a) Prescription medications
Find out whether the patient is taking prescription
medications from more than one doctor.
b) Non-prescription medications
Many patients forget to tell their doctor about their
non-prescription medications. These can be extremely
important causes of drug toxicity, and are occasionally
involved in drug interactions.
Specific categories of drugs to inquire about include:
i) Over-the-counter drugs (antacids,
analgesics, H2 antagonists, etc.).
ii) Health foods and vitamins
iii) Alternative medicines (herbal, homeopathy
etc.)
iv) Drugs of abuse, illicit drugs.
c) Food and timing of meals
Many medications need to be carefully timed with regard
to meals or food to maximise bioavailability. Furthermore,
some foods have been shown to alter the pharmacokinetics
of certain drugs. For example, in large quantities,
grapefruit juice is a significant inhibitor of cytochrome
P450 3A4, and can raise the concentrations of saquinavir
by up to 3-fold.
Two additional questions to ask the patient are:
i) Is the patient aware of the fed/fasting
requirements for the medications he or she is taking?
ii) Does the patient have any unusual dietary
habits that might affect the drugs he or she is taking?
|
|
|
2 Can
the patient identify what drugs he/she is taking?
|
It may be worthwhile to visually
inspect all medications the patient is taking. It is
good to ensure that what the patient is actually taking,
and what they think they are taking, are one and the
same. For example, the names nevirapine and nelfinavir
are very confusing.
|
|
|
3 Is the patient taking the
drugs as prescribed?
|
a) Assessing adherence
Partial adherence is extremely common. Evaluating drug
interactions requires knowledge of how much medication
the patient has taken, and when. A neutral approach
to adherence history is preferred. Open-ended questions
may prove more helpful than close-ended questions.
b) How important is non-compliance,
underdosing, overdosing, and altered dose intervals?
For antiretroviral agents, good adherence is very important
in assuring long-term anti-HIV activity and preventing
resistance. In addition, increasing or decreasing drug
dose, or increasing or decreasing dosing interval, may
have a major impact on drug interactions. The impact
can be significant, as most drug interactions are a
direct function of drug concentration over time. This
is especially true for metabolic inhibition interactions,
and pharmacodynamic interactions.
c) What are some strategies
to increase adherence with the regimen?
A thorough understanding of HIV therapy, including the
importance of good adherence and the dangers of poor
adherence, is an important basic tool to increasing
adherence. Diaries and calendars may improve adherence.
Learning the patients' daily routine and incorporating
dosing cues into that routine may also increase adherence.
The construction of a regimen using the minimum number
of agents, using combination products (e.g. Duovir),
and selecting drugs which are given once or twice-daily
may be useful. It is also important to provide positive
feedback for a successful response.
|
|
|
4 Does the patient
understand the effects and side effects of all the
medications that have been prescribed?
|
It is important that the HIV physician counsel patients
about what they can expect and what they need to know,
when starting a new medication. For example, a patient
initiating therapy with ritonavir should be extensively
counseled on the gastrointestinal side effects that
are likely to occur, especially during the first few
weeks of therapy. Such information can greatly increase
adherence to the regimen.
Many of the medications used in the management of HIV
infection have overlapping side effects. Patients should
be counseled about the signs and symptoms of adverse
effects (such as numbness and tingling in the extremities
with peripheral neuropathy), and instructed to contact
their physician if any of these symptoms occur.
|
|
|
| |